Year: 2023

logo_m

Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen’s Hybrozyme™ Technology

DAEJEON, South Korea--(BUSINESS WIRE)--#ALTB4--Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Sandoz...